Antihyperglycaemic Efficacy, Response Prediction and Dose—Response Relations of Treatment with Metformin and Sulphonylurea, Alone and in Primary Combination
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
The short‐term (2–12 weeks) antihyperglycaemic efficacy of metformin (M), glibenclamide (G), and their primary combination (MG) was assessed in a double‐blind study including 165 unselected patients with Type 2 diabetes. Patients with diet failure were randomized to M, G or MG. The dose was titrated with a fasting blood glucose concentration (FBG) of < 6.7 mmol I−1 as the target, using at most six dose levels, the first three comprising increasing monotherapy (M or G) or low‐dose primary combination (MGL), and the second three add‐on therapies (M/G and G/M) and primary combination therapy escalated to high dose (MGH). Success rates were higher on MGL than on monotherapy. The difference in achieving acceptable control (FBG ≤ 7.8 mmol I−1) was 70% versus 51% (95% confidence interval 3–36%, p = 0.032). When the drugs were combined, a slightly greater FBG reduction (p = 0.026) was observed, at lower dosage (p = 0.013). The response could not be predicted from body weight, but depended upon initial FBG (p = 0.019) and meal‐stimulated C‐peptide (p = 0.007). FBG declined progressively with increasing doses of metformin, whereas glibenclamide exerted most of its effect at low dose. Primary combination therapy with metformin and sulphonylurea may be clinically useful.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Groop, L. C. (1992) · Diabetes Care · doi:10.2337/diacare.15.6.737 · Cited by 408
Cited by
Clinical pharmacokinetics of metformin
Graham, G. G., Punt, J., Arora, M., Day, R. O., Doogue, M. P., Duong, J. K., Furlong, T. J., Greenfield, J. R., Greenup, L. C., Kirkpatrick, C. M., et al. (2011) · Clinical Pharmacokinetics · doi:10.2165/11534750-000000000-00000 · Cited by 1,318
“Support for monitoring the plasma concentrations comes from the observation that the clinical response to metformin increases with increasing dose and, further, that a higher dose ofmetformin is required in patients with higher pretreatment fasting blood glucose levels.([103]) The monitoring of plasma concentrations o…”
BackgroundEffect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action
Shu, Y., Sheardown, S. A., Brown, C., Owen, R. P., Zhang, S., Castro, R. A., Ianculescu, A. G., Yue, L., Lo, J. C., Burchard, E. G., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30558 · Cited by 967
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter (posthumous), E. E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002967.pub4 · Cited by 893
A practical review of C-peptide testing in diabetes
Leighton, E., Sainsbury, C. A., & Jones, G. C. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0265-4 · Cited by 773
“Higher MMTT stimulated c-peptide has been shown to be present in patients who respond to metformin and glibenclamide in combination but GST c-peptide did not predict response to glibenclamide alone [42, 43].”
BackgroundClinical Pharmacokinetics of Metformin
Scheen, A. J. (1996) · Clinical Pharmacokinetics · doi:10.2165/00003088-199630050-00003 · Cited by 636
Metadata
- Authors
- Hermann, L. S., Scherstén, B., & Melander, A.
- Venue
- Diabetic Medicine
- Publisher
- Wiley
- Published
- 1994-12
- Volume
- 11
- Issue
- 10
- Pages
- 953-960
- ISSN
- 0742-3071 (ISSN-L)
- 1464-5491
- OpenAlex
- W2166640752
- Cited by
- 87
- References
- 1
- FWCI
- 1.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antihyperglycaemic Efficacy, Response Prediction and Dose—Response Relations of Treatment with Metformin and Sulphonylurea, Alone and in Primary Combination. https://app.cochat.ai/papers/10.1111/j.1464-5491.1994.tb00253.x
- The paper
- Hermann, L. S., Scherstén, B., & Melander, A. (1994). Antihyperglycaemic Efficacy, Response Prediction and Dose—Response Relations of Treatment with Metformin and Sulphonylurea, Alone and in Primary Combination. Diabetic Medicine. https://doi.org/10.1111/j.1464-5491.1994.tb00253.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.